ArticleDigestive diseases and sciences2026
Temporal Trends and Socio-Demographic Disparities in Inflammatory Bowel Disease: Insights from the Global Burden of Disease Study 2021.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) is a chronic immune-mediated gastrointestinal disorder with rising global incidence, especially in industrializing regions. The Global Burden of Disease Study (GBD) framework enables standardized assessment of this growing health challenge.
aimsTo assess temporal trends and socio-demographic disparities in the global burden of IBD from 1990 to 2021 and to project future disease trajectories.
methodsWe obtained data on IBD incidence, mortality, and disability-adjusted life years (DALYs) for 204 countries and territories from 1990 to 2021. Temporal trends were assessed using Joinpoint regression. Future burden from 2022 to 2040 was projected using Bayesian age-period-cohort modeling. Associations with the socio-demographic index (SDI) were examined via Spearman's rank correlation test. Cross-country inequalities in IBD burden were quantified using the slope index of inequality (SII) and concentration index.
resultsBetween 1990 and 2021, global age-standardized incidence rate (ASIR) of IBD increased [average annual percentage change (AAPC) = 0.16], whereas age-standardized mortality rate (ASMR) (AAPC = - 0.49) and age-standardized DALY rate (ASDR) (AAPC = - 0.57) declined. By 2040, the ASIR, ASMR, and ASDR of IBD are projected to decrease to 4.18, 0.41, and 15.06 per 100,000, respectively. The highest burden was observed in high-SDI regions, particularly Australasia, North America, and Western Europe. From 1990 to 2021, absolute inequalities in IBD incidence (SII: 4.12-6.89) and mortality (SII: 0.35-0.48) widened.
conclusionIBD burden has grown unequally across socio-demographic strata. Despite mortality and DALY reductions, rising incidence and inequalities necessitate targeted prevention and early intervention strategies.
Indexed as
Identifiers
42668343What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.